ReviewTopics in antiviral medicine
Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation.
Review in Topics in antiviral medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?AIDS (London, England) · 2018Pooled it
- Estimating the costs and perceived benefits of oral pre-exposure prophylaxis (PrEP) delivery in ten counties of Kenya: a costing and a contingent valuation study.Frontiers in reproductive health · 2024Article
- From Innovation to Implementation: The Evolution of HIV Pre-Exposure Prophylaxis and Future Implications.Pathogens (Basel, Switzerland) · 2023Review
- A Review of HIV Pre-exposure Prophylaxis Streamlining Strategies.Current HIV/AIDS reports · 2020Review
- Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.Journal of acquired immune deficiency syndromes (1999) · 2017Article
- Preexposure Prophylaxis of HIV Infection: the Role of Clinical Practices in Ending the HIV Epidemic.Current HIV/AIDS reports · 2017Review
- Patterns of drug use and HIV infection among adults in a nationally representative sample.Addictive behaviors · 2017Article
- Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach.Journal of the International AIDS Society · 2017Review
- HIV and Bone Complications: Understudied Populations and New Management Strategies.Current HIV/AIDS reports · 2016Review
- Women want Pre-Exposure Prophylaxis but are Advised Against it by Their HIV-positive Counterparts.Journal of AIDS & clinical research · 2015Article
- Awareness and Willingness to use Condoms and Preexposure Prophylaxis among Gay, Bisexual, and Other Cisgendered Men who Have sex with men in Slum Communities in Ghana. BSGH-004.Journal of the International Association of Providers of AIDS CareArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preexposure prophylaxis (PrEP) with tenofovir and emtricitabine has been shown to be effective and cost-effective in preventing acquisition of HIV infection. However, PrEP has not yet been widely adopted in the clinical practice setting. Data thus far, although imperfect, do not indicate an increase in risk behaviors in the setting of PrEP, although potential risk compensation outside of the clinical trial setting should be further examined. Substantial work remains to implement and support PrEP use, including identification of optimal settings for providing and managing PrEP, identification of methods to ensure optimal adherence to treatment, and employment of strategies to deliver PrEP to populations at greatest risk. This article summarizes a presentation made by Raphael J. Landovitz, MD, MSc, at the 2015 Conference on Retroviruses and Opportunistic Infections held from February 23 to February 26 in Seattle, Washington.
Indexed as
Identifiers
26200708PMC6148938W1038214955What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.